PRNewsWire
03 Nov 2025, 12:00 UTC · 46w ago
Verdict
Headline takes no side. We score QDEL +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
QuidelOrtho received FDA 510(k) clearance for its VITROS hs Troponin I Assay to aid in the diagnosis of myocardial infarction.
More positive than 76% of claims this week
The commercial rollout of the VITROS hs Troponin I Assay for U.S. laboratories will begin later in 2025.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 49% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The company received FDA 510(k) clearance for its VITROS hs Troponin I Assay, expanding its product menu and diagnostic capabilities.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−59.8%
Price is moving against the score
$10.86 vs $26.99 close before publication (Oct 31) · not market-adjusted
QDEL chart →